Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WOnDER-BT
NCT06058988Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2023
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in brain cancer, glioblastoma (GBM), metastatic cancer and 1 more (3 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Intraoperative plasma concentrations in brain tumors after T-DXd injections up to 24 months. Started Sep 2023; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
brain cancerglioblastoma (GBM)metastatic cancerleptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT06058988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058988.